tiprankstipranks
Trending News
More News >
Comera Life Sciences Holdings Inc. (CMRA)
:CMRA
US Market
Advertisement

Comera Life Sciences Holdings (CMRA) Price & Analysis

Compare
26 Followers

CMRA Stock Chart & Stats

$0.01
$0.00(0.00%)
At close: 4:00 PM EST
$0.01
$0.00(0.00%)

Comera Life Sciences Holdings News

CMRA FAQ

What was Comera Life Sciences Holdings Inc.’s price range in the past 12 months?
Currently, no data Available
What is Comera Life Sciences Holdings Inc.’s market cap?
Currently, no data Available
When is Comera Life Sciences Holdings Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Comera Life Sciences Holdings Inc.’s earnings last quarter?
Currently, no data Available
Is Comera Life Sciences Holdings Inc. overvalued?
According to Wall Street analysts Comera Life Sciences Holdings Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
    Does Comera Life Sciences Holdings Inc. pay dividends?
    Comera Life Sciences Holdings Inc. does not currently pay dividends.
    What is Comera Life Sciences Holdings Inc.’s EPS estimate?
    Comera Life Sciences Holdings Inc.’s EPS estimate for its next earnings report is not yet available.
    How many shares outstanding does Comera Life Sciences Holdings Inc. have?
    Currently, no data Available
    What happened to Comera Life Sciences Holdings Inc.’s price movement after its last earnings report?
    Currently, no data Available
    Which hedge fund is a major shareholder of Comera Life Sciences Holdings Inc.?
    Currently, no hedge funds are holding shares in CMRA

    Company Description

    Comera Life Sciences Holdings Inc.

    Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
    Similar Stocks
    Company
    Price & Change
    Follow
    AIM ImmunoTech
    Q/C Technologies
    Salarius Pharmaceuticals
    Scinai Immunotherapeutics
    Oragenics

    Ownership Overview

    1.03%98.97%
    Insiders
    Mutual Funds
    1.03% Other Institutional Investors
    98.97% Public Companies and
    Individual Investors

    Options Prices

    Currently, No data available
    ---
    Popular Stocks
    What am I Missing?
    Make informed decisions based on Top Analysts' activity
    Know what industry insiders are buying
    Get actionable alerts from top Wall Street Analysts
    Find out before anyone else which stock is going to shoot up
    Get powerful stock screeners & detailed portfolio analysis